On 6th Sep 2012, Germany company Fresenius Kabi (FK) stated they proposed initial investment of 25 million euros (about 200 million yuan) to set up an R & D center and production base for antineoplastic drug in Wuhan Optical Valley. This is an important part of global business for the introduction of global core pharmaceutical business to China, before that FK's nutrition therapy, infusion therapy and medical equipment had already entered into Chinese market.

<Back >